Home › NDC Lookup › Ingredients › Levonorgestrel › 70700-0164-06
Levonorgestrel 1.5 mg Tablet, 1 tablet — NDC 70700-0164-06 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Levonorgestrel 1.5 mg Tablet, 1 tablet — NDC 70700-164-06 (Billing 70700-0164-06)

by Xiromed LLC · 1 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK

This is a package of 1 tablet of Levonorgestrel 1.5 mg Tablet from Xiromed LLC, marketed since Mar 2020 and currently FDA-listed; retail pharmacies pay about $6.33 per tablet (NADAC). It is this product's only package size.

NDC 70700-0164-06
🏷️ FDA NDC (as labeled) 70700-164-06 billing pads the product segment with a zero
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70700-164-06 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
70700 labeler · 164 product · 06 package
Package marketed since
Mar 13, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
1 EA per package
Barcode (UPC)
0370700164068
Medicaid fills, this package
25,567 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70700-164-06
Product NDC 70700-164
11-digit billing NDC 70700016406
NCPDP billing unit EA — each (per item)
RxCUI 483325
UNII 5W7SIA7YZW
UPC 0370700164068
Application # ANDA205329
SPL Set ID 626a2333-ff56-ef28-a287-b33bacc0302a
Established class (EPC) Progestin; Progestin-containing Intrauterine System
Physiologic effect Inhibit Ovum Fertilization
Chemical class Progesterone Congeners
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-03-13
Route ORAL
Dosage form TABLET
Substance LEVONORGESTREL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 25400040000340
GPI class Levonorgestrel
GCN Seq No 058193
GCN 23549
HICL code 007318
Ingredient (HICL) Levonorgestrel
HIC1 code G
Therapeutic class — broad (HIC1) Female Genital System
HIC2 code G8
Therapeutic class — intermediate (HIC2) Systemic Antifertility Agents
HIC3 code G8A
Therapeutic class — specific (HIC3) Contraceptives,Oral
AHFS code 68:12.00.00
AHFS class Contraceptives
FDB label name LEVONORGESTREL 1.5 MG TABLET
FDB brand name Levonorgestrel
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 058193
  • GCN: 23549
  • GPI-14 (Medi-Span): 25400040000340
  • HICL (First Databank): 007318
  • AHFS class code: 68:12.00.00
  • RxCUI (RxNorm): 483325
Why two NDCs? The FDA registers this code as 70700-164-06 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70700-0164-06. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Progestin class.

Pharmacologic class Progestin, Progestin-containing Intrauterine System
Drug family (ATC) Progestogens and estrogens, sequential preparations, Progestogens, Emergency contraceptives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LEVONORGESTREL 1.5 MG TABLET Ingredient Levonorgestrel
📗 Our plain-language guide HelloPharmacist
  • It comes in two main types. The intrauterine systems (Mirena, Liletta, Kyleena, Skyla) prevent pregnancy for years, and Mirena and Liletta also treat heavy menstrual bleeding. The...
  • Take it as soon as you can, within 72 hours (3 days) of unprotected sex. The sooner you take it, the better it works. If you vomit within 2 hours, call a healthcare professional to...
  • How do I take the emergency contraceptive tablet?
  • No. It's a backup method and isn't as effective as regular birth control. It also won't work if you're already pregnant, and it doesn't protect against HIV or other STDs.
📖 Read our full Levonorgestrel guide →
2
Nutrient depletion considerations

Levonorgestrel may be associated with lower levels of 2 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Levonorgestrel nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $6.331 $6.33 / 1 tablet
Medicaid paysCMS SDUD · 12 mo $14.21 $14.21 / 1 tablet
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $10.215 $6.318
▼ Down 30% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70700-0164-06 You're viewing this Main listing 1 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK 2020-03-13 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Option 2 1.5 mg 00113-2003-12 L. 1 tablet $6.331 — Availability likely —
Levonorgestrel 1.5 mg 00536-1433-63 Rugby 1 tablet $6.331 — Availability likely —
New Day 1.5 mg 16714-0809-01 Northstar 1 tablet $6.331 — Availability likely —
EContra One-Step 1.5 mg 50102-0211-13 Afaxys 3 tablets $6.331 — Availability likely —
My Choice TM 1.5 mg 62756-0720-60 SUN 1 tablet $6.331 — Availability likely —
My Way 1.5 mg 68180-0852-11 Lupin 1 tablet $6.331 — Availability likely —
Levonorgestrel 1.5 mgthis 70700-0164-06 Xiromed 1 tablet $6.331 — Availability likely —
Her Style 1.5 mg 50742-0352-01 Ingenus 1 tablet $6.797 — FDA listed +7%
Opcicon One-Step 1.5 mg 62756-0718-60 Sun 1 tablet $6.797 — FDA listed +7%
Levonorgestrel 1.5 mg 40032-0622-30 Novel 1 tablet — — FDA listed —
My Way 1.5 mg 43386-0622-30 Lupin 1 tablet — — FDA listed —
Plan B One-Step 1.5 mg 50090-5978-00 A-S 1 tablet — — FDA listed —
My Choice 1.5 mg 51660-0096-11 OHM 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 51660-0723-11 Ohm 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 51660-0999-11 Ohm 1 tablet — — FDA listed —
Fem Choice morning after 1.5 mg 58602-0712-28 Aurohealth 1 tablet — — FDA listed —
Athentia Next 1.5 mg 58602-0721-57 Aurohealth 1 tablet — — FDA listed —
Econ Morning After 1.5 mg 58602-0841-48 Aurohealth 3 tablets — — FDA listed —
After Banger 1.5 mg 58602-0891-57 Aurohealth 1 tablet — — FDA listed —
Ithappenz Morning After 1.5 mg 58602-0892-57 Aurohealth 1 tablet — — FDA listed —
Levonorgestrel Tablet, 1.5 mg 59556-0282-01 Strides 1 tablet — — FDA listed —
Optionelle 1.5 mg 59556-0286-01 Strides 1 tablet — — FDA listed —
Emergency Contraceptive 1.5 mg 59726-0138-01 P 1 tablet — — Discontinued —
AfterPlan 1.5 mg 62756-0723-60 SUN 1 tablet — — FDA listed —
AfterPill 1.5 mg 64122-0605-01 Syzygy 1 tablet — — FDA listed —
My Way 1.5 mg 68071-4294-01 NuCare 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 69230-0333-32 Camber 1 tablet — — FDA listed —
Aftera 1.5 mg 69536-0103-88 Foundation 1 tablet — — FDA listed —
Next Choice One Dose 1.5 mg 69536-0133-88 Foundation 1 tablet — — FDA listed —
Plan B One-Step 1.5 mg 69536-0146-19 Foundation 1 tablet — — FDA listed —
Plan B One-Step 1.5 mg 69536-0162-88 Foundation 1 tablet — — FDA listed —
Take Action 1.5 mg 69536-0200-88 Foundation 1 tablet — — FDA listed —
Morning After 1.5 mg/1.5mg 69953-0515-01 Rapha 1 mg — — FDA listed —
Morning After 1.5 mg/1.5mg 69953-0516-01 Rapha 1 mg — — FDA listed —
Morning After 1.5 mg/1.5mg 69953-0517-01 Rapha 1 mg — — FDA listed —
PostDay One-Step 1.5 mg/1.5mg 69953-0617-42 Rapha 1 mg — — FDA listed —
PostDay One-Step 1.5 mg/1.5mg 69953-0618-43 Rapha 1 mg — — FDA listed —
PostDay One-Step 1.5 mg/1.5mg 69953-0628-60 Rapha 1 mg — — FDA listed —
LEADER Emergency Contraceptive Levonorgestrel 1.5 mg 70000-0600-01 Cardinal 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 70000-0675-01 LEADER/ 1 tablet — — FDA listed —
My Choice TM 1.5 mg 71205-0120-01 Proficient 1 tablet — — FDA listed —
My Way 1.5 mg 71205-0361-01 Proficient 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 71713-0098-11 Thirty 1 tablet — — FDA listed —
Amazon Basic Care Levonorgestrel 1.5 mg 72288-0324-28 Amazon.com 1 tablet — — FDA listed —
SheWise 1.5 mg 72657-0108-11 GLENMARK 1 tablet — — Discontinued —
Levonorgestrel 1.5 mg 72657-0123-11 GLENMARK 1 tablet — — FDA listed —
Morning After Pill 1.5 mg 73436-2859-01 Cadence 1 tablet — — FDA listed —
Morning After Pill 1.5 mg 73436-8292-01 Cadence 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 73581-0217-01 YYBA 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 79929-0016-01 Naari 1 tablet — — FDA listed —
Restart 1.5 mg 80584-0103-01 Winx 1 tablet — — FDA listed —
Julie Morning After Pill 1.5 mg 82791-0002-01 Julie 1 tablet — — FDA listed —
Julie Morning After Pill 1.5 mg 82791-0003-01 Julie 1 tablet — — FDA listed —
Julie 1.5 mg 82791-0335-01 Julie 1 tablet — — FDA listed —
Julie 1.5 mg 82791-0532-01 Julie 1 tablet — — FDA listed —
Julie 1.5 mg 82791-0538-01 Julie 1 tablet — — FDA listed —
PostDay One-Step 1.5 mg 85506-0100-10 Home 1 tablet — — FDA listed —
Option 2 1.5 mg 00113-8099-12 L. 1 tablet — — FDA listed —
Levonorgestrel 1.5 mg 73581-0017-01 YYBA 1 tablet — — FDA listed —
Julie Morning After Pill 1.5 mg 82791-0004-01 Julie 1 tablet — — FDA listed —
My After Plan 1.5 mg 51660-0098-11 OHM 1 tablet — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Mar 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintC;1
Size6 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Levonorgestrel inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII LQA7B6G8JG
    A synthetic polymer made by combining water-soluble compounds. It acts as a surfactant and solubilizer to help mix oil and water-based ingredients, improving the medicine's texture and how active ingredients dissolve.

5 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 188

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerXiromed LLC
Application holderXIROMED PHARMA ESPANA SL
FDA applicationANDA205329 (ANDA)
Labeler code70700
First marketedMar 2020
Product typeHuman Otc Drug
Portfolio39 products on file

More NDCs from Xiromed LLC labeler code 70700

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Keep Out of Reach of Children 📄 Questions or Comments 📖 Instructions for Use 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 23 words ▾

Use for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control)

⏱️ Dosage and Administration 72 words ▾

When should I use levonorgestrel tablet 1.5 mg? The sooner you take emergency contraception, the better it works. You should use levonorgestrel tablet 1.5 mg within 72 hours (3 days) after you have had unprotected sex. Levonorgestrel tablet 1.5 mg is a backup or emergency method of birth control you can use when: • your regular birth control was used incorrectly or failed • you did not use any birth control method

⚠️ Warnings 31 words ▾

Warnings Allergy alert: Do not use if you have ever had an allergic reaction to levonorgestrel Sexually transmitted diseases (STDs) alert: This product does not protect against HIV/AIDS or other STDs

📦 Storage and Handling 105 words ▾

Store at 20–25°C (68–77°F) Active ingredient: levonorgestrel 1.5 mg Inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 188 1-844-947-6633 www.xiromed.com If you are sexually active, you should see a healthcare provider for routine checkups. Your healthcare provider will talk to you about and, if necessary, test you for sexually transmitted diseases, teach you about effective methods of routine birth control, and answer any other questions you may have.

XIROMED, LLC. Levonorgestrel tablet 1.5 mg Manufactured by: Laboratorios León Farma S.A. C/La Vallina s/n Poligono Industrial de Navatejera 24008 Villaquilambre, León, Spain Manufactured for: Xiromed, LLC.

Florham Park, NJ 07932 164-06-01 Rev. 09/2023

🧪 Active Ingredient 5 words ▾

Active ingredient Levonorgestrel 1.5 mg

🧪 Inactive Ingredients 12 words ▾

Inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 188

🎯 Purpose 3 words ▾

Purpose Emergency contraceptive

📄 Do Not Use 48 words ▾

Do not use if you are already pregnant (because it will not work) for regular birth control Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of levonorgestrel.

📄 When Using This Product 28 words ▾

When using this product you may have • menstrual changes • tiredness • breast pain • nausea • headache • vomiting • lower stomach (abdominal) pain • dizziness

📄 Keep Out of Reach of Children 21 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control center right away.

📄 Questions or Comments 6 words ▾

Questions? Call 1-844-947-6633 Monday-Friday 9AM-5PM EST

📖 Instructions for Use 47 words ▾

Directions take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work. if you vomit within 2 hours after taking the medication, call a healthcare professional to find out if you should repeat the dose

📄 Package Label / Principal Display Panel 32 words ▾

Priciple Display Panel - Blister

Principle Display Panel - Carton Levonorgestrel Tablet (levonorgestrel) tablet 1.5 mg Emergency contraceptive Reduces chance of pregnancy after unprotected sex. Not for regular birth control. Xiromed LLC.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
25.6K
Units reimbursed last 4 qtrs
26.2K
Gross reimbursed last 4 qtrs
$372.5K
Avg / prescription
$14.57
Avg / unit
$14.2057
Latest quarter Q1 2026
4KRx
Medicaid pays / ea
$14.2057
gross reimbursed
vs
NADAC / ea
$6.3306
acquisition cost
=
Spread
+$7.8751
+124% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
51% FFS 49% MCO
Fee-for-service · 12,972 Rx Managed care · 12,595 Rx
State Medicaid map
Alaska: no data reported AK Maine: 162 units · 11.6 per 100k residents ME Washington: 156 units · 2.0 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 333 units · 5.8 per 100k residents MN Wisconsin: 645 units · 10.9 per 100k residents WI Michigan: 388 units · 3.9 per 100k residents MI New York: 5,075 units · 25.9 per 100k residents NY Vermont: 26 units · 4.0 per 100k residents VT New Hampshire: 14 units · 1.0 per 100k residents NH Oregon: 295 units · 7.0 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 14 units · 0.4 per 100k residents IA Illinois: 2,680 units · 21.4 per 100k residents IL Indiana: 428 units · 6.2 per 100k residents IN Ohio: 1,239 units · 10.5 per 100k residents OH Pennsylvania: 2,740 units · 21.1 per 100k residents PA New Jersey: 528 units · 5.7 per 100k residents NJ Massachusetts: 2,773 units · 39.6 per 100k residents MA California: 5,648 units · 14.5 per 100k residents CA Utah: no data reported UT Colorado: 142 units · 2.4 per 100k residents CO Nebraska: 11 units · 0.6 per 100k residents NE Missouri: 158 units · 2.6 per 100k residents MO Kentucky: 56 units · 1.2 per 100k residents KY West Virginia: 57 units · 3.2 per 100k residents WV Virginia: 244 units · 2.8 per 100k residents VA Maryland: 791 units · 12.8 per 100k residents MD Connecticut: 256 units · 7.1 per 100k residents CT Rhode Island: 455 units · 41.6 per 100k residents RI Arizona: 47 units · 0.6 per 100k residents AZ New Mexico: 142 units · 6.7 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 12 units · 0.2 per 100k residents TN North Carolina: 282 units · 2.6 per 100k residents NC South Carolina: 39 units · 0.7 per 100k residents SC Delaware: 34 units · 3.3 per 100k residents DE Oklahoma: no data reported OK Louisiana: 14 units · 0.3 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 55 units · 0.5 per 100k residents GA D.C.: 183 units · 27.0 per 100k residents DC Hawaii: 23 units · 1.6 per 100k residents HI Texas: 78 units · 0.3 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
0.241.6
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 41.6 /100k
2 Massachusetts 39.6 /100k
3 D.C. 27.0 /100k
4 New York 25.9 /100k
5 Illinois 21.4 /100k
6 Pennsylvania 21.1 /100k
7 California 14.5 /100k
8 Maryland 12.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Mirena (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Mirena. CMS lists 4 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$198.1K
Claims incl. refills
161
Beneficiaries
160
Spend / beneficiary
$1,238.34
Spend / claim
$1,230.65
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for LEVONORGESTREL — the ingredient across all brands.

Top reported reactions

Device Expulsion45,536
Device Dislocation20,447
Menstruation Irregular15,061
Vaginal Haemorrhage15,056
Genital Haemorrhage11,164
Abdominal Pain Lower9,317
Nausea8,806

Age at onset

Neonate87
Infant54
Child25
Adolescent1,518
Adult62,663
Elderly189

Reporter sex

206,325 reports
Male · 1%
Female · 99%
Unknown · 0%

Serious outcomes

Hospitalization11,401
Disabling2,217
Life-threatening2,086
Death309
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 11,815 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 70700-0163-01 · Xiromed, 70700-0165-25 · Xiromed →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.